» Articles » PMID: 24247134

Contemporary Diversity of β-lactamases Among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-avibactam Activity Tested Against Isolates Producing the Most Prevalent β-lactamase Groups

Overview
Specialty Pharmacology
Date 2013 Nov 20
PMID 24247134
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Escherichia coli (328 isolates), Klebsiella pneumoniae (296), Klebsiella oxytoca (44), and Proteus mirabilis (33) isolates collected during 2012 from the nine U.S. census regions and displaying extended-spectrum-β-lactamase (ESBL) phenotypes were evaluated for the presence of β-lactamase genes, and antimicrobial susceptibility profiles were analyzed. The highest ESBL rates were noted for K. pneumoniae (16.0%, versus 4.8 to 11.9% for the other species) and in the Mid-Atlantic and West South Central census regions. CTX-M group 1 (including CTX-M-15) was detected in 303 strains and was widespread throughout the United States but was more prevalent in the West South Central, Mid-Atlantic, and East North Central regions. KPC producers (118 strains [112 K. pneumoniae strains]) were detected in all regions and were most frequent in the Mid-Atlantic region (58 strains). Thirteen KPC producers also carried blaCTX-M. SHV genes encoding ESBL activity were detected among 176 isolates. Other β-lactamase genes observed were CTX-M group 9 (72 isolates), FOX (10), TEM ESBL (9), DHA (7), CTX-M group 2 (3), NDM-1 (2 [Colorado]), and CTX-M groups 8 and 25 (1). Additionally, 62.9% of isolates carried ≥2 β-lactamase genes. KPC producers were highly resistant to multiple agents, but ceftazidime-avibactam (MIC50/90, 0.5/2 μg/ml) and tigecycline (MIC50/90, 0.5/1 μg/ml) were the most active agents tested. Overall, meropenem (MIC50, ≤0.06 μg/ml), ceftazidime-avibactam (MIC50, 0.12 to 0.5 μg/ml), and tigecycline (MIC50, 0.12 to 2 μg/ml) were the most active antimicrobials when tested against this collection. NDM-1 producers were resistant to all β-lactams tested. The diversity and increasing prevalence of β-lactamase-producing Enterobacteriaceae have been documented, and ceftazidime-avibactam was very active against the vast majority of β-lactamase-producing strains isolated from U.S. hospitals.

Citing Articles

Molecular epidemiology of extended-spectrum beta-lactamase-producing- species in East Tennessee dairy cattle farms.

Gelalcha B, Mohamed R, Gelgie A, Kerro Dego O Front Microbiol. 2024; 15:1439363.

PMID: 39380685 PMC: 11458399. DOI: 10.3389/fmicb.2024.1439363.


Xpert Carba-R Assay on Flagged Blood Culture Samples: Clinical Utility in Intensive Care Unit Patients with Bacteremia Caused by .

Rajendran S, Gopalakrishnan R, Tarigopula A, Kumar D, Nambi P, Sethuraman N Indian J Crit Care Med. 2023; 27(9):655-662.

PMID: 37719341 PMC: 10504648. DOI: 10.5005/jp-journals-10071-24533.


Molecular epidemiology of antimicrobial resistance in central africa: A systematic review.

Dikoumba A, Onanga R, Mangouka L, Boundenga L, Ngoungou E, Godreuil S Access Microbiol. 2023; 5(8).

PMID: 37691840 PMC: 10484317. DOI: 10.1099/acmi.0.000556.v5.


Clinically Isolated β-Lactam-Resistant Gram-Negative Bacilli in a Philippine Tertiary Care Hospital Harbor Multi-Class β-Lactamase Genes.

Abordo A, Carascal M, Remenyi R, Dalisay D, Saludes J Pathogens. 2023; 12(8).

PMID: 37623979 PMC: 10459468. DOI: 10.3390/pathogens12081019.


High risk of bloodstream infection of carbapenem-resistant enterobacteriaceae carriers in neutropenic children with hematological diseases.

Liu L, Lin Q, Yang W, Chen X, Liu F, Chen X Antimicrob Resist Infect Control. 2023; 12(1):66.

PMID: 37422680 PMC: 10329308. DOI: 10.1186/s13756-023-01269-1.


References
1.
Spanu T, De Angelis G, Cipriani M, Pedruzzi B, DInzeo T, Cataldo M . In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother. 2012; 56(8):4516-8. PMC: 3421558. DOI: 10.1128/AAC.00234-12. View

2.
Castanheira M, Sader H, Farrell D, Mendes R, Jones R . Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother. 2012; 56(9):4779-85. PMC: 3421892. DOI: 10.1128/AAC.00817-12. View

3.
Castanheira M, Mendes R, Rhomberg P, Jones R . Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Resist. 2008; 14(3):211-6. DOI: 10.1089/mdr.2008.0827. View

4.
Bogdanovich T, Adams-Haduch J, Tian G, Nguyen M, Kwak E, Muto C . Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis. 2011; 53(4):373-6. PMC: 3202324. DOI: 10.1093/cid/cir401. View

5.
Stachyra T, Levasseur P, Pechereau M, Girard A, Claudon M, Miossec C . In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother. 2009; 64(2):326-9. PMC: 2707266. DOI: 10.1093/jac/dkp197. View